Letter to the Editor

Pathologic activation of thrombopoietin receptor and JAK2-STAT5 pathway by frameshift mutants of mouse calreticulin

  • Subscribe to Leukemia for full access:

    $1031

    Subscribe

Additional access options:

Already a subscriber?  Log in  now or  Register  for online access.

References

  1. 1.

    , , , , , et al. Somatic mutations of calreticulin in myeloproliferative neoplasms. N Engl J Med 2013; 369: 2379–2390.

  2. 2.

    , , , , , et al. Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2. N Engl J Med 2013; 369: 2391–2405.

  3. 3.

    , , , , , et al. Thrombopoietin receptor activation by myeloproliferative neoplasm associated calreticulin mutants. Blood 2015; e-pub ahead of print 14 December 2015; doi:10.1182/blood-2015-11-681932.

  4. 4.

    , , , , , et al. Calreticulin mutants in mice induce an MPL-dependent thrombocytosis with frequent progression to myelofibrosis. Blood 2015; e-pub ahead of print 25 November 2015; doi:10.1182/blood-2015-11-679571.

  5. 5.

    , , , , . Calreticulin: one protein, one gene, many functions. Biochem J 1999; 344: 281–292.

  6. 6.

    , , , , , et al. MARIMO cells harbor a CALR mutation but are not dependent on JAK2/STAT5 signaling. Leukemia 2015; 29: 494–497.

  7. 7.

    , , , , , et al. A novel myeloid cell line, Marimo, derived from therapy-related acute myeloid leukemia during treatment of essential thrombocythemia: consistent chromosomal abnormalities and temporary C-MYC gene amplification. Cancer Genet Cytogenet 1998; 100: 21–24.

  8. 8.

    , , , , , et al. Orientation-specific signalling by thrombopoietin receptor dimers. EMBO J 2011; 30: 4398–4413.

  9. 9.

    , , , , , et al. A JAK1/JAK2 chimera can sustain alpha and gamma interferon responses. Mol Cell Biol 1997; 17: 695–706.

  10. 10.

    , , , , , et al. Multiplex genome engineering using CRISPR/Cas systems. Science 2013; 339: 819–823.

  11. 11.

    , , , , , . Generation of mutant mice by pronuclear injection of circular plasmid expressing Cas9 and single guided RNA. Sci Rep 2013; 3: 3355.

  12. 12.

    , , . JAK inhibitor in CALR-mutant myelofibrosis. N Engl J Med 2014; 370: 1168–1169.

  13. 13.

    , , , . Calreticulin: a new horizon for the testing and treatment of myeloproliferative neoplasms. Expert Rev Hematol 2014; 7: 423–425.

  14. 14.

    , , , , , et al. Thrombopoietin receptor is required for the oncogenic function of CALR mutants. Leukemia 2016; 30: 1759–1763.

  15. 15.

    , , , , , et al. JAK2 or CALR mutation status defines subtypes of essential thrombocythemia with substantially different clinical course and outcomes. Blood 2014; 123: 1544–1551.

Download references

Acknowledgements

We thank Dr Patrick Jacquemin for the support with CRISPR/Cas9 approach and Dr Nicolas Dauguet for expert cell sorting. IP is supported by Institut National du Cancer (PLBIO2015); Agence Nationale de la Recherche; (ANR-13-JVSV1-GERMPN-01, I.P.) and Institut National de la Santé et de la Recherche Médicale, Genetics of Hematological Disorders (Inserm). IP, WV and CM are supported by a grant form la Ligue Nationale contre le Cancer (HR 2013, 2016). Support to SNC was from the Ludwig Institute for Cancer Research, FRS-FNRS, Salus Sanguinis Foundation, the Action de Recherche Concertée project ARC10/15–027 of the Université catholique de Louvain, the Fondation contre le Cancer, the PAI Programs BCHM61B5 and Belgian Medical Genetics Initiative. Support from Télévie (IC and TB), FSR (TB) and FRS-FNRS (CP) is acknowledged. HN and RK acknowledge the support received by Austrian Science Fund (FWF: project numbers- F2812-B20 and F4702-B20).

Author information

Affiliations

  1. Ludwig Institute for Cancer Research Brussels, Brussels, Belgium

    • T Balligand
    • , C Pecquet
    • , I Chachoua
    •  & S N Constantinescu
  2. SIGN Pole, de Duve Institute, Université catholique de Louvain, Brussels, Belgium

    • T Balligand
    • , C Pecquet
    • , I Chachoua
    •  & S N Constantinescu
  3. LPAD Pole, de Duve Institute, Université catholique de Louvain, Brussels, Belgium

    • Y Achouri
  4. Genetics of Hematological Disorders, CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences, Vienna, Austria

    • H Nivarthi
    •  & R Kralovics
  5. INSERM, UMR1170, Villejuif, France

    • C Marty
    • , W Vainchenker
    •  & I Plo
  6. Paris-Saclay, UMR1170, Villejuif, France

    • C Marty
    • , W Vainchenker
    •  & I Plo
  7. Gustave Roussy, UMR1170, Villejuif, France

    • C Marty
    • , W Vainchenker
    •  & I Plo

Authors

  1. Search for T Balligand in:

  2. Search for Y Achouri in:

  3. Search for C Pecquet in:

  4. Search for I Chachoua in:

  5. Search for H Nivarthi in:

  6. Search for C Marty in:

  7. Search for W Vainchenker in:

  8. Search for I Plo in:

  9. Search for R Kralovics in:

  10. Search for S N Constantinescu in:

Competing interests

The authors declare no conflict of interest.

Corresponding author

Correspondence to S N Constantinescu.

Supplementary information

Supplementary Information accompanies this paper on the Leukemia website (http://www.nature.com/leu)